These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 8565379)
21. Indium-111 satumomab pendetide: the first FDA-approved monoclonal antibody for tumor imaging. Bohdiewicz PJ J Nucl Med Technol; 1998 Sep; 26(3):155-63; quiz 170-1. PubMed ID: 9755434 [TBL] [Abstract][Full Text] [Related]
22. Clinical experience with radiolabelled monoclonal antibodies in the detection of colorectal and ovarian carcinoma recurrence and review of the literature. Pinkas L; Robins PD; Forstrom LA; Mahoney DW; Mullan BP Nucl Med Commun; 1999 Aug; 20(8):689-96. PubMed ID: 10451876 [TBL] [Abstract][Full Text] [Related]
24. Splenic metastasis from colon carcinoma imaged using In-111 OncoScint. Pieslor PC; White CA; Varney RR Clin Nucl Med; 1995 Jun; 20(6):553-4. PubMed ID: 7648747 [No Abstract] [Full Text] [Related]
25. Intense uptake of In-111 satumomab pendetide in an inflammatory mass. Silberstein EB; Saeks E Clin Nucl Med; 1996 Jan; 21(1):53-5. PubMed ID: 8741891 [TBL] [Abstract][Full Text] [Related]
26. Radiation absorbed dose estimates for indium-111-labeled B72.3, an IgG antibody to ovarian and colorectal cancer: MIRD dose estimate report No. 18. Mardirossian G; Brill AB; Harwood SJ; Olsen J; Dwyer KA; Siegel JA J Nucl Med; 1998 Apr; 39(4):671-6. PubMed ID: 9544680 [No Abstract] [Full Text] [Related]
27. Role of In-111 labeled CYT-103 immunoscintigraphy in the evaluation of patients with recurrent colorectal carcinoma. Markowitz A; Saleemi K; Freeman LM Clin Nucl Med; 1993 Aug; 18(8):685-700. PubMed ID: 8403703 [TBL] [Abstract][Full Text] [Related]
28. Monoclonal antibody imaging in colon cancer: a transition from basic science to clinical application. Kim SL; Goldschmid S Am J Gastroenterol; 1994 Oct; 89(10):1910-2. PubMed ID: 7942701 [No Abstract] [Full Text] [Related]
29. Immunoscintigraphy with 111In-satumomab pendetide in patients with colorectal adenocarcinoma: performance and impact on clinical management. Corman ML; Galandiuk S; Block GE; Prager ED; Weiner GJ; Kahn D; Abdel-Nabi H; Mitchell EP; Pascucci VL; Maroli AN Dis Colon Rectum; 1994 Feb; 37(2):129-37. PubMed ID: 8306832 [TBL] [Abstract][Full Text] [Related]
30. Oncoscint for detection of disseminated colorectal and ovarian cancer. Med Lett Drugs Ther; 1993 Jun; 35(898):52-3. PubMed ID: 8497207 [No Abstract] [Full Text] [Related]
33. Lipomas as a potential cause for uptake of In-111 MAb72.3 (Oncoscint CR). Sakow NK; Japanwalla M; Tuckson WB; Shields RE Clin Nucl Med; 1996 Apr; 21(4):332-3. PubMed ID: 8925626 [No Abstract] [Full Text] [Related]
34. Dose escalation trial of indium-111-labeled anti-carcinoembryonic antigen chimeric monoclonal antibody (chimeric T84.66) in presurgical colorectal cancer patients. Wong JY; Chu DZ; Yamauchi D; Odom-Maryon TL; Williams LE; Liu A; Esteban JM; Wu AM; Primus FJ; Beatty JD; Shively JE; Raubitschek AA J Nucl Med; 1998 Dec; 39(12):2097-104. PubMed ID: 9867150 [TBL] [Abstract][Full Text] [Related]